It has been suggested that 5-fluorouracil (5-FU) and gemcitabine promote inflammasome activation to induce the IL-1β production in MDSCs, which increases IL-17 secretion by CD4+ T cells to weaken anticancer efficacy of these chemotherapeutic drugs towards B16F10 melanoma, 4T1 mammary carcinoma, and Lewis lung carcinoma (LLC) [50]. Here, CD4 is linked to melanoma.